| Page 1270 | Kisaco Research
 

Lorenz Leitner

Neuro-urologist
Balgrist University

Lorenz Leitner

Neuro-urologist
Balgrist University

Lorenz Leitner

Neuro-urologist
Balgrist University
 

Paul Garofolo

CEO
Locus Biosciences

Paul Garofolo

CEO
Locus Biosciences

Paul Garofolo

CEO
Locus Biosciences
 

Felipe Molina PhD

Professor
University of Extremadura

My research is focused on bacterial genetics, the cell cycle of microorganisms and phages as biocontrol agents in dairy products.

Felipe Molina PhD

Professor
University of Extremadura

Felipe Molina PhD

Professor
University of Extremadura

My research is focused on bacterial genetics, the cell cycle of microorganisms and phages as biocontrol agents in dairy products.

 

Alexander Sulakvelidze

President & CEO
Intralytix

Dr. Alexander “Sandro” Sulakvelidze, Ph.D. is the President and CEO of Intralytix.  He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage-based food safety product in the World. Dr. Sulakvelidze has published extensively on the subject of phage therapy and biocontrol, including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of 15 issued and several pending patents in the field of bacteriophage technology. 

Alexander Sulakvelidze

President & CEO
Intralytix

Alexander Sulakvelidze

President & CEO
Intralytix

Dr. Alexander “Sandro” Sulakvelidze, Ph.D. is the President and CEO of Intralytix.  He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage-based food safety product in the World. Dr. Sulakvelidze has published extensively on the subject of phage therapy and biocontrol, including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of 15 issued and several pending patents in the field of bacteriophage technology. 

 

Christian Röhrig

Director of Operations
Micreos

Christian Röhrig

Director of Operations
Micreos

Christian Röhrig

Director of Operations
Micreos
 

Merav Bassan

Chief Development Officer
BiomX

Dr. Bassan was most recently Vice President Head of Translational Sciences at Teva Pharmaceutical Industries, Inc., where she was responsible for early stages of clinical development via translation from animal data to human. Prior to this role, Dr. Bassan served as Vice President of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women‘s health, endocrinology, GI, biosimilars and other areas. Overall, Dr.

Merav Bassan

Chief Development Officer
BiomX

Merav Bassan

Chief Development Officer
BiomX

Dr. Bassan was most recently Vice President Head of Translational Sciences at Teva Pharmaceutical Industries, Inc., where she was responsible for early stages of clinical development via translation from animal data to human. Prior to this role, Dr. Bassan served as Vice President of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women‘s health, endocrinology, GI, biosimilars and other areas. Overall, Dr. Bassan has over 20 years of leadership experience with clinical and drug development teams in her various roles at Teva Pharmaceutical and other smaller biotech companies. Dr. Bassan is also a member of the Israeli 8400 health network, a cross-sector network of leaders actualizing the global disruptive capabilities of Israel’s HealthTech ecosystem. Dr. Bassan holds a Ph.D. in Neuroscience from the Tel-Aviv University Sackler School of Medicine and completed a post-doctoral fellowship in Neuroscience at Harvard University.

 

Daniel Weber

Counsel
Wenger Vieli Ltd.

Daniel S. Weber is a counsel at Wenger Vieli Ltd., a leading Swiss law firm with offices in Zurich and Zug. He is a member of the firm's white-collar crime & compliance, internal investigations and financial services teams, with broad experience in private practice and in-house, as well as with the Swiss regulator FINMA.

Mr. Weber mainly works in the areas of white-collar and cybercrime, compliance and internal investigations, as well as in banking and financial market law including Fintech.

Daniel Weber

Counsel
Wenger Vieli Ltd.

Daniel Weber

Counsel
Wenger Vieli Ltd.

Daniel S. Weber is a counsel at Wenger Vieli Ltd., a leading Swiss law firm with offices in Zurich and Zug. He is a member of the firm's white-collar crime & compliance, internal investigations and financial services teams, with broad experience in private practice and in-house, as well as with the Swiss regulator FINMA.

Mr. Weber mainly works in the areas of white-collar and cybercrime, compliance and internal investigations, as well as in banking and financial market law including Fintech.

Based on his prior experience as deputy head investigations at a major Swiss bank and as a secondee in the enforcement division of FINMA, Mr. Weber has in-depth knowledge of the financial services industry and broad experience in conducting large-scale investigations, including whistleblowing proceedings.

Mr. Weber serves as the co-chair of the working group on compliance & investigations of the Zurich Bar Association as well as a part-time prosecutor of the Office of the Swiss Armed Forces Attorney General, where he is a department head and litigates in military courts.